Modality
Degrader
MOA
SHP2i
Target
CD38
Pathway
JAK/STAT
MG
Development Pipeline
Preclinical
May 2022
→ Jun 2029
PreclinicalCurrent
NCT06020980
21 pts·MG
2022-05→TBD·Not yet recruiting
NCT05174104
1,785 pts·MG
2023-08→2029-06·Not yet recruiting
1,806 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-203.2y awayInterim· MG
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2029-06-20 · 3.2y away
MG
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06020980 | Preclinical | MG | Not yet recr... | 21 | UPDRS |
| NCT05174104 | Preclinical | MG | Not yet recr... | 1785 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |